Fosun gains pair of cell therapies from ReNeuron

ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE